Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1997-04-01
2000-04-04
Goldberg, Jerome D.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514344, 514345, 514349, 514351, 514340, A61K 3144
Patent
active
060462167
ABSTRACT:
Derivatives of phenyl pyridinone are useful for the treatment of patients having precancerous lesions. These compounds are also useful to inhibit the growth of neoplastic cells.
REFERENCES:
patent: 3031450 (1962-04-01), Fischer et al.
patent: 3161654 (1964-12-01), Shen
patent: 3322755 (1967-05-01), Roch et al.
patent: 3517005 (1970-06-01), Cronin et al.
patent: 3594480 (1971-07-01), Cronin et al.
patent: 3647858 (1972-03-01), Hinkley et al.
patent: 3654349 (1972-04-01), Shen et al.
patent: 3780040 (1973-12-01), Schnettler et al.
patent: 3812127 (1974-05-01), Cronin et al.
patent: 3819631 (1974-06-01), Broughton et al.
patent: 3920636 (1975-11-01), Takahasi et al.
patent: 4001237 (1977-01-01), Partyka et al.
patent: 4001238 (1977-01-01), Partyka et al.
patent: 4039544 (1977-08-01), Broughton et al.
patent: 4060615 (1977-11-01), Matier et al.
patent: 4079057 (1978-03-01), Juby et al.
patent: 4098788 (1978-07-01), Crenshaw et al.
patent: 4101548 (1978-07-01), Crenshaw et al.
patent: 4102885 (1978-07-01), Crenshaw et al.
patent: 4138561 (1979-02-01), Crenshaw et al.
patent: 4146718 (1979-03-01), Jenks et al.
patent: 4161595 (1979-07-01), Kaplan et al.
patent: 4171363 (1979-10-01), Crenshaw et al.
patent: 4208521 (1980-06-01), Crenshaw et al.
patent: 4209623 (1980-06-01), Juby
patent: 4423075 (1983-12-01), Dvornik et al.
patent: 4460590 (1984-07-01), Moller
patent: 4460591 (1984-07-01), DeGraw et al.
patent: 4885301 (1989-12-01), Coates
patent: 4923874 (1990-05-01), McMahon et al.
patent: 5073559 (1991-12-01), Coates
patent: 5147875 (1992-09-01), Coates et al.
patent: 5223501 (1993-06-01), Chakravarty et al.
patent: 5250535 (1993-10-01), Verheyden et al.
patent: 5254571 (1993-10-01), Coates et al.
patent: 5358952 (1994-10-01), Moschel et al.
patent: 5401774 (1995-03-01), Pamukcu et al.
Waddell, W.R. et al., Am. J. Surgery, vol. 157, pp. 175-179 (1989).
Gonzaga, R.A.F. et al., The Lancet, Mar. 30, 1985, p. 751.
Waddell, W.R. et al., J. Surg. Onocology, vol. 24, pp. 83-87 (1983).
Federation Proceedings (1972) of the Federation of American Societies for Experimental Biology abstract Nos. 2044 and 2045.
Gilman, S.C. et al., Nonsteroidal Anti-inflammatory Drugs in Cancer Therapy, (circa 1985).
Brogden, R.N. et al., Drugs, vol. 16, pp. 97-114 (1978).
Hucker, H.B. et al., Drug Metabolism & Disposition, vol. 1, No. 6, pp. 721-736 (1973).
Shen, T.Y. et al., Chemical and Biological Studies on Indomethacin, Sulindac and Their Analogs, pp. 107-178 (circa 1975).
Duggan, E. E. et al., Clin. Pharm. & Therapeutics, vol. 21, No. 3, pp. 326-335 (1976).
Duggan, D.E. et al., J. Pharm. & Exper. Therap., vol. 201, No. 1, pp. 8-13 (1977).
Glavin, G.B. et al., Toxicology and Applied Pharmacology, vol. 83, pp. 386-389 (1986).
Moorghen, M. et al., Journal of Pathology, vol. 156, pp. 341-347 (1988).
Moorghen, M. et al., Acta Histochemica, Suppl.--Band XXIX, S. 195-199 (1990).
Bjarnason et al., Gastroenterology, vol. 94, No. 4, pp. 1070-1074 (1988).
Badrieh, Y., et al., Chem. Ber., vol. 125, pp. 667-674 (1992).
Silvola, J. et al., Effects of nonsteroidal anti-inflammatory drugs on rat gastric mucosal phosphodiesterase activity, Agents and Actions, vol. 12.4, pp. 516-520 (1982).
Curtis-Prior, P.B. et al., Cyclic Nucleotide Phosphodiesterase Activity of Human Normal and Carcinomatous Lung Tissue, The Lancet, pp. 1225-1225 Dec. 4, 1976.
Pepin, P. et al., Effects of Sulindac and Oltipraz on the tumorigenicity of 4-(methylnitrosamino)1-(3-pyridyl)-1-Butanone in A/J mouse lung, Carcinogenesis, vol. 13, No. 3, pp. 341-348 (1992).
Nicholson, C.D. et al. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes, Trends Pharmacol. Sci. (TiPS), vol. 12, pp. 19-27 (1991).
Ahn, H.S. et al., Effects of Selective Inhibitors on Cyclic Nucleotide Phosphodiesterases of Rabbit Aorta, Biochemical Pharmacology, vol. 38, No. 19, pp. 3331-3339 (1989).
Luginer, C. et al., Selective Inhibition of Cyclic Nucleotide Phosphodiesterases of Human, Bovine and Rat Aorta, Biochem. Pharmacology, vol. 35, No. 10, pp. 1743-1751 (1986).
Turner, N.C. et al., Relaxation of guinea-pig trachea by cyclic AMP phosphodiesterase inhibitors and their enhancement by sodium mitroprusside, Br. J. Pharmacol. vol. III, pp. 1047-1052 (1994).
Weishaar, R.E. et al., Multiple Molecular Forms of Cyclic Nucleotide Phosphodiesterase in Cardiac and Smooth Muscle and In Platelets, Biochem. Pharmacology, vol. 35, No. 5, pp. 787-800 (1986).
Murray, K.J. et al., Potential Use of Selective Phosphodiesterase Inhibitors in the Treatment of Asthma, New Drugs for Asthma Therapy, Birkhauser Verlag Basel, pp. 27-46 (1991).
Saeki, T. et al., Isolation of Cyclic Nucleotide Phosphodiesterase Isozymes From Pig Aorta, Biochem. Pharmacology, vol. 46, No. 5, pp. 833-839 (1993).
Turner, N.C. et al., Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in anaesthetized guinea-pig, Br. J. Pharmacol., vol. 111, 1198-1204 (1994).
Ferreira, S.H. et al., The molecular mechanism of action of peripheral morphone analgesia: stimulation of the cGMP system via nitric oxide release, European Journal of Pharmacology, 201 pp. 121-122 (1991).
Hidaka, H. et al., Selective Inhibitors of Three Forms of Cyclic Nucleotide Phosphodiesterase--Basic and Potential Clinical Applications, vol. 16, Advances in Cyclic Nucleotide and Protein Phosphorylation Research, pp. 245-259 (1984).
Tulshian, D. et al., Synthesis and Phosphodiesterase Activity of Carboxylic Acid Mimetics of Cyclic Guanosine 3",5"-Monophosphate, J. Med. Chem, vol. 36, 1210-1220 (1993).
Yasumoto, T. et al., Properties of Base-Substituted and Carboxyl-Esterified Analogues of Griseolic Acid, a Potent cAMP Phosphodiesterase Inhibitor, Biochemical Pharmacology, vol. 43, No. 10, pp. 2073,2081 (1992).
Broughton, B.J. et al., Antiallergic Activity of 2-Phenyl-8-azapruin-6-ones, Journal of Medicinal Chemistry, vol. 18, No. 11, pp. 1117-1118 (1975).
Kodama, K. et al., Effects of a novel, selective and potent phosphodiesterase type V inhibitor, E4021, on myocardial ischemia in guinea pigs, Euro. J. of Pharma. 263, pp. 93-99 (1994).
Zacharski, L. R. et al., Effect of Mopidamol on Survival in Carcinoma of the Lung and Colon: Final Report of Veterans Administration Cooperative Study No. 188, J. of the Nat'l. Cancer Inst., vol. 80, No. 2, pp. 90-96 (1998).
Lichtner, R. B. et al., The Pyrimido-pyrimidine Derivatives RA 233 adn RX-RA 85 affect Growth and Cytoskeletal Organization of Rat Mammary Adenocarcinoma Cells, Eur. J. Cancer Clin. Oncol., vol. 23, No. 9, pp. 1269-1275 (1987).
Janik, P. et al., Inhibition of Growth of Primary and Metastatic Lewis Lung Carcinoma Cells by the Phosphodiesterase Inhibitor Isobutylmethylxanthine, Cancer Res. vol. 40, pp. 1950-1954, (Jun. 1980).
Bergstrand, Hakan et al., Effects of Antiallergic Agents, Compound 48/80, and Some Reference Inhibitors on the Activity of Partially Purified Human Lung Tissue Adenosine Cyclic 3',5'-Monophosphate and Guanosine Cyclic 3',5'-Monophosphate Phosphodiesterases, Molecular Pharmacology, 13, pp. 38-43 (1976).
Drees, Markus et al., 3',5'-Cyclic Nucleotide Phosphodiesterase in Tumor Cells as Potential Target for Tumor Growth Inhibition, Cancer Research 53, pp. 3058-3061 (1993).
Semmler, J. et al., Xanthine derivatives: comparison between suppression of tumor necrosis factor-x production and inhibition of cAMP phosphodiesterase activity, Immunology 78, pp. 520-525 (1993).
Mehta, Rajendra et al., Structure-Activity Relationships of Brassinin in Preventing the Development of Carcinogen-Induced Mammary Lesions in Organ Culture, Anticancer Research 14: 1209-1214 (1994).
Makaryan, A.P. et al., Cyclic Nucleotides in Patients with Malignant Neoplasms of the Colon, Laboratornoe Delo, vol. 8, pp. 31-33 (1991).
Clarke, W.R. et al., The type III phosphodiesterase inhibitor milrinone and type V PDE inhibitor dipyridamole individually and synergistically reduce elevated pulmonary vascular resistance (Abstract Only), Pulm. Pharmacol., 7(2), pp. 81-9, (1994).
Raeburn, David et al., Effects of isoenzyme-s
Pamukcu Rifat
Piazza Gary
Cell Pathways Inc.
Goldberg Jerome D.
Stevenson Robert W.
LandOfFree
Method of treating a patient having precancerous lesions with ph does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating a patient having precancerous lesions with ph, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating a patient having precancerous lesions with ph will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-365623